Recovery and long-term function after hematopoietic cell transplantation for leukemia or lymphoma

Karen L. Syrjala, Shelby Langer, Janet R. Abrams, Barry Storer, Jean E. Sanders, Mary E D Flowers, Paul J. Martin

Research output: Contribution to journalArticle

226 Citations (Scopus)

Abstract

Context: Hematopoietic cell transplantation (HCT) is an effective and widely used treatment for hematologic malignancies. The rate and predictors of physical and emotional recovery after HCT have not been adequately defined in prospective long-term studies. Objective: To examine the course of recovery and return to work after HCT. Design, Setting, and Patients: Prospective, longitudinal cohort study at a US academic center specializing in HCT. Function was assessed from pretransplantation to 5-year follow-up for 319 adults who had myeloablative HCT for treatment of leukemia or lymphoma and spoke English. Of the 99 long-term survivors who had no recurrent malignancy, 94 completed 5-year follow-up. Main Outcome Measures: Physical limitations, return to work, depression, and distress related to treatment or disease were evaluated before transplantation, at 90 days, and at 1, 3, and 5 years after HCT. Results: Physical recovery occurred earlier than psychological or work recovery. Only 21 patients (19%) recovered on all outcomes at 1 year. The proportion without major limitations increased to 63% (n=57) by 5 years. Among survivors without recurrent malignancy, 84% (n = 74) returned to full-time work by 5 years. Patients with slower physical recovery had higher medical risk and were more depressed before HCT (P≤.001). Patients with chronic graft-vs-host disease (P=.01), with less social support before HCT (P=.001), and women (P<.001) were more depressed after transplantation. Transplant-related distress was slower to recover for allogeneic transplant recipients and those with less social support before HCT (P≤.01). Patients who had more experience with cancer treatment before beginning HCT had more rapid recovery from depression (P=.04) and treatment-related distress (P=.009). Conclusions: Full recovery after HCT is a 3- to 5-year process. Recovery might be accelerated by more effective interventions to increase work-related capabilities, improve social support, and manage depression.

Original languageEnglish (US)
Pages (from-to)2335-2343
Number of pages9
JournalJournal of the American Medical Association
Volume291
Issue number19
DOIs
StatePublished - May 19 2004
Externally publishedYes

Fingerprint

Cell Transplantation
Lymphoma
Leukemia
Social Support
Return to Work
Survivors
Transplantation
Therapeutics
Neoplasms
Graft vs Host Disease
Hematologic Neoplasms
Longitudinal Studies
Cohort Studies
Outcome Assessment (Health Care)
Psychology
Transplants

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Recovery and long-term function after hematopoietic cell transplantation for leukemia or lymphoma. / Syrjala, Karen L.; Langer, Shelby; Abrams, Janet R.; Storer, Barry; Sanders, Jean E.; Flowers, Mary E D; Martin, Paul J.

In: Journal of the American Medical Association, Vol. 291, No. 19, 19.05.2004, p. 2335-2343.

Research output: Contribution to journalArticle

Syrjala, Karen L. ; Langer, Shelby ; Abrams, Janet R. ; Storer, Barry ; Sanders, Jean E. ; Flowers, Mary E D ; Martin, Paul J. / Recovery and long-term function after hematopoietic cell transplantation for leukemia or lymphoma. In: Journal of the American Medical Association. 2004 ; Vol. 291, No. 19. pp. 2335-2343.
@article{d052d5dc95344b3c9a4859d3bbc325f0,
title = "Recovery and long-term function after hematopoietic cell transplantation for leukemia or lymphoma",
abstract = "Context: Hematopoietic cell transplantation (HCT) is an effective and widely used treatment for hematologic malignancies. The rate and predictors of physical and emotional recovery after HCT have not been adequately defined in prospective long-term studies. Objective: To examine the course of recovery and return to work after HCT. Design, Setting, and Patients: Prospective, longitudinal cohort study at a US academic center specializing in HCT. Function was assessed from pretransplantation to 5-year follow-up for 319 adults who had myeloablative HCT for treatment of leukemia or lymphoma and spoke English. Of the 99 long-term survivors who had no recurrent malignancy, 94 completed 5-year follow-up. Main Outcome Measures: Physical limitations, return to work, depression, and distress related to treatment or disease were evaluated before transplantation, at 90 days, and at 1, 3, and 5 years after HCT. Results: Physical recovery occurred earlier than psychological or work recovery. Only 21 patients (19{\%}) recovered on all outcomes at 1 year. The proportion without major limitations increased to 63{\%} (n=57) by 5 years. Among survivors without recurrent malignancy, 84{\%} (n = 74) returned to full-time work by 5 years. Patients with slower physical recovery had higher medical risk and were more depressed before HCT (P≤.001). Patients with chronic graft-vs-host disease (P=.01), with less social support before HCT (P=.001), and women (P<.001) were more depressed after transplantation. Transplant-related distress was slower to recover for allogeneic transplant recipients and those with less social support before HCT (P≤.01). Patients who had more experience with cancer treatment before beginning HCT had more rapid recovery from depression (P=.04) and treatment-related distress (P=.009). Conclusions: Full recovery after HCT is a 3- to 5-year process. Recovery might be accelerated by more effective interventions to increase work-related capabilities, improve social support, and manage depression.",
author = "Syrjala, {Karen L.} and Shelby Langer and Abrams, {Janet R.} and Barry Storer and Sanders, {Jean E.} and Flowers, {Mary E D} and Martin, {Paul J.}",
year = "2004",
month = "5",
day = "19",
doi = "10.1001/jama.291.19.2335",
language = "English (US)",
volume = "291",
pages = "2335--2343",
journal = "JAMA - Journal of the American Medical Association",
issn = "0002-9955",
publisher = "American Medical Association",
number = "19",

}

TY - JOUR

T1 - Recovery and long-term function after hematopoietic cell transplantation for leukemia or lymphoma

AU - Syrjala, Karen L.

AU - Langer, Shelby

AU - Abrams, Janet R.

AU - Storer, Barry

AU - Sanders, Jean E.

AU - Flowers, Mary E D

AU - Martin, Paul J.

PY - 2004/5/19

Y1 - 2004/5/19

N2 - Context: Hematopoietic cell transplantation (HCT) is an effective and widely used treatment for hematologic malignancies. The rate and predictors of physical and emotional recovery after HCT have not been adequately defined in prospective long-term studies. Objective: To examine the course of recovery and return to work after HCT. Design, Setting, and Patients: Prospective, longitudinal cohort study at a US academic center specializing in HCT. Function was assessed from pretransplantation to 5-year follow-up for 319 adults who had myeloablative HCT for treatment of leukemia or lymphoma and spoke English. Of the 99 long-term survivors who had no recurrent malignancy, 94 completed 5-year follow-up. Main Outcome Measures: Physical limitations, return to work, depression, and distress related to treatment or disease were evaluated before transplantation, at 90 days, and at 1, 3, and 5 years after HCT. Results: Physical recovery occurred earlier than psychological or work recovery. Only 21 patients (19%) recovered on all outcomes at 1 year. The proportion without major limitations increased to 63% (n=57) by 5 years. Among survivors without recurrent malignancy, 84% (n = 74) returned to full-time work by 5 years. Patients with slower physical recovery had higher medical risk and were more depressed before HCT (P≤.001). Patients with chronic graft-vs-host disease (P=.01), with less social support before HCT (P=.001), and women (P<.001) were more depressed after transplantation. Transplant-related distress was slower to recover for allogeneic transplant recipients and those with less social support before HCT (P≤.01). Patients who had more experience with cancer treatment before beginning HCT had more rapid recovery from depression (P=.04) and treatment-related distress (P=.009). Conclusions: Full recovery after HCT is a 3- to 5-year process. Recovery might be accelerated by more effective interventions to increase work-related capabilities, improve social support, and manage depression.

AB - Context: Hematopoietic cell transplantation (HCT) is an effective and widely used treatment for hematologic malignancies. The rate and predictors of physical and emotional recovery after HCT have not been adequately defined in prospective long-term studies. Objective: To examine the course of recovery and return to work after HCT. Design, Setting, and Patients: Prospective, longitudinal cohort study at a US academic center specializing in HCT. Function was assessed from pretransplantation to 5-year follow-up for 319 adults who had myeloablative HCT for treatment of leukemia or lymphoma and spoke English. Of the 99 long-term survivors who had no recurrent malignancy, 94 completed 5-year follow-up. Main Outcome Measures: Physical limitations, return to work, depression, and distress related to treatment or disease were evaluated before transplantation, at 90 days, and at 1, 3, and 5 years after HCT. Results: Physical recovery occurred earlier than psychological or work recovery. Only 21 patients (19%) recovered on all outcomes at 1 year. The proportion without major limitations increased to 63% (n=57) by 5 years. Among survivors without recurrent malignancy, 84% (n = 74) returned to full-time work by 5 years. Patients with slower physical recovery had higher medical risk and were more depressed before HCT (P≤.001). Patients with chronic graft-vs-host disease (P=.01), with less social support before HCT (P=.001), and women (P<.001) were more depressed after transplantation. Transplant-related distress was slower to recover for allogeneic transplant recipients and those with less social support before HCT (P≤.01). Patients who had more experience with cancer treatment before beginning HCT had more rapid recovery from depression (P=.04) and treatment-related distress (P=.009). Conclusions: Full recovery after HCT is a 3- to 5-year process. Recovery might be accelerated by more effective interventions to increase work-related capabilities, improve social support, and manage depression.

UR - http://www.scopus.com/inward/record.url?scp=2442590643&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2442590643&partnerID=8YFLogxK

U2 - 10.1001/jama.291.19.2335

DO - 10.1001/jama.291.19.2335

M3 - Article

C2 - 15150205

AN - SCOPUS:2442590643

VL - 291

SP - 2335

EP - 2343

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0002-9955

IS - 19

ER -